ALSO READZydus Cadila receives tentative approval for Sitagliptin and Metformin Hydrochloride Tablets Zydus Cadila gets USFDA approval to market Mesalamine Delayed - Release Tablets USP, 1.2 g Zydus Cadila receives USFDA approval Zydus Cadila receives final approval for Diflunisal Tablets Zydus Cadila receives final approval for Felbamate Tablets
From USFDAZydus Cadila has received the tentative approval from USFDA to market Mesalamine Suppositories for rectal use, 1000 mg.
Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis. It will be produced at the group's Topical Plant at Ahmedabad.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)